Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed Products

Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed Products


Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada. The pseudoephedrine-containing NEXAFED brand products utilize Acura's IMPEDEA Technology which disrupts the extraction and conversion of the pseudoephedrine into the illicit drug, methamphetamine.



from Biotech News